CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Stock Price, Financials & Summary

Price chart

Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20

Key dataOct 20, 2026

Open$308.84

From 52W high+0.00%

Volume1.27M

Market cap$15.06B

P/E (TTM)—

P/S (TTM)3.8x

Div yield—

Key dataOct 20, 2026

Open

$308.84

From 52W high

+0.00%

Volume

1.27M

Market cap

$15.06B

ValuationView details →

P/E (Fwd)

25.0x

EV/EBITDA

81.2x

P/E (TTM)

—

RSI (14)

65.5

MomentumView details →

1D Return

+5.14%

YTD Return

+58.74%

SummaryUpdated Jun 1, 2026

Charles River Laboratories International, Inc. (NYSE:CRL) is a leading contract research organization founded in 1947 and headquartered in Wilmington, Massachusetts. The company went public in 2000 and has grown to become one of the world's largest providers of non-clinical drug development services to the pharmaceutical and biotechnology industries. Charles River operates globally across the United States, Europe, Canada, and the Asia Pacific region, serving as a critical partner in the drug discovery and development process by providing essential testing services, research models, and manufacturing solutions that help bring new medicines to market.

Ask drillr about CHARLES RIVER LABORATORIES INTERNATIONAL, INC. →

ValuationView details →

P/E (Fwd)

25.0x

P/E (TTM)

—

EV/EBITDA

81.2x

EV/Sales

4.5x

P/S (TTM)

3.8x

P/B (TTM)

5.3x

ProfitabilityView details →

Gross Margin

32.24%

Net Margin

−5.96%

EBITDA Margin

5.51%

ROE (TTM)

−8.40%

ROA (TTM)

−3.17%

Asset Turnover

0.52x

GrowthView details →

Revenue YoY

−0.74%

EPS YoY

—

FCF YoY

−35.94%

Revenue CAGR 3Y

+0.33%

EPS CAGR 3Y

—

EBITDA YoY

−58.27%

MomentumView details →

1D Return

+5.14%

YTD Return

+58.74%

1Y Return

+68.20%

RSI (14)

65.5

vs 50D SMA

+9.07%

vs 200D SMA

+46.49%

Capital & dividendView details →

Debt/Equity

1.07x

Current Ratio

1.35x

Quick Ratio

1.04x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$3.02

EPS Surprise

9.03%

Beats (12Q)

11/12

Next Q EPS Est

$3.33

Avg Surprise (4Q)

−80.57%

Rev Surprise

2.40%

Financials snapshotView financials →

Revenue (TTM)

4.00B

Net Income (TTM)

−238.46M

Op. CF (TTM)

582.15M

Next earningsNov 4, 2026 →

Latest newsMore news →

CTIBIOTECH and Beijing Vital River signed a memorandum of understanding and strategic partnership to bring CTIBIOTECH’s human tissue bioassays and New Approach Methodologies to China.5d ago

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. announced that it will release third-quarter 2026 earnings and hold a conference call.12d ago

Similar companies

金域医学603882.SH ICON Public Limited CompanyICLR Medpace Holdings, Inc.MEDP Revvity, Inc.RVTY 安图生物603658.SH Joinn Laboratories(China)Co.,Ltd.06127.HK Find similar companies →

Latest newsMore news →

CTIBIOTECH and Beijing Vital River signed a memorandum of understanding and strategic partnership to bring CTIBIOTECH’s human tissue bioassays and New Approach Methodologies to China.5d ago CHARLES RIVER LABORATORIES INTERNATIONAL, INC. announced that it will release third-quarter 2026 earnings and hold a conference call.12d ago